Numan's Premium Positioning Risk
Numan
This risk is really about who gets paid for the care layer versus who gets paid for the drug. Numan can charge premium prices today because it bundles prescribing, fulfillment, coaching, lab follow up, and app based support into one subscription. That works best when medication access is hard and fragmented. Once the same GLP-1s are easier to source through lower cost rivals, pharmacy chains, or manufacturer linked channels, more of the customer decision shifts to monthly price.
-
Numan is not just selling a prescription. Its weight loss plans start at £179 per month and include clinician review, coach messaging, side effect management, scheduled blood tests, and pharmacy fulfillment. That service bundle supports higher pricing, but it also gives competitors a clear target to unbundle or match more cheaply.
-
The strongest price pressure comes from players with better drug access. Hims announced its ZAVA acquisition on June 3, 2025 to expand across the UK and Europe. Ro integrated with NovoCare Pharmacy on April 29, 2025 after Novo Nordisk launched the channel on March 5, 2025, showing how scaled telehealth platforms can plug directly into manufacturer supply and lower cash pay pricing.
-
A useful comparison is Yazen, which charges about €90 per month for the care layer and has patients buy medication separately from partner pharmacies. That model makes the service fee legible to consumers. If Europe moves in that direction, Numan will need to prove that its all in package delivers enough better retention, outcomes, or convenience to justify the spread.
The market is heading toward a split. Basic medication access will get cheaper and more standardized, while the winners in premium digital obesity care will be the companies that can show better adherence, better dose management, and better long term retention. For Numan, that means future pricing power will depend less on access to GLP-1s and more on whether its care experience measurably improves results.